Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00521
|
|||||
| Drug Name |
Clonidine
|
|||||
| Synonyms |
1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-(9CI); 2,6-Dichloro-N-2-imidazolidinylidenebenzenamine; 2,6-dichloro-N-(2-imidazolidinylidene)aniline; 2,6-dichloro-N-2-imidazolidinylidenebenzenamide; 2,6-dichloro-N-imidazolidin-2-ylideneaniline; 2-((2,6-Dichlorophenyl)imino)imidazolidine; 2-(2,6-Dichloroanilino)-1,3-diazacyclopentene-(2);2-(2,6-Dichloroanilino)-2-imidazoline; 2-(2,6-Dichlorophenylamino)-2-imidazoline; 2-(2,6-Dichlorophenylimino)imidazolidine; 2-Imidazoline, 2-(2,6-dichloroanilino)-(7CI,8CI); 2-[(2,6-Dichlorophenyl)imino]imidazoline; 2-[(2,6-dichlorophenyl)imino]-2-imidazoline; 734571A; Adesipress; CATAPRES-TTS-1; CATAPRES-TTS-2; CATAPRES-TTS-3; Catapres (TN); Catapres-TTS; Catapresan; Catapressan; Catarpres; Catarpres-TTS; Catarpres-TTS (TN); Catarpresan; Chlornidinum; Clofenil; Clonidin; Clonidina; Clonidina [INN-Spanish]; Clonidine (JAN/USAN/INN); Clonidine [USAN:BAN:INN]; Clonidinhydrochlorid; Clonidinum; Clonidinum [INN-Latin]; Clopheline; Dixarit; Duraclon; Duraclont; Gemiton; Hemiton; Isoglaucon; Klofelin; Klofenil; M 5041T; M-5041T; N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine; SKF 34427; ST 155BS; ST-155-BS; ST-155BS; Tenso-Timelets
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | High blood pressure [ICD11: BA00] | Approved | [1] | |||
| Therapeutic Class |
Antihypertensive Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C9H9Cl2N3
|
|||||
| Canonical SMILES |
C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl
|
|||||
| InChI |
InChI=1S/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14)
|
|||||
| InChIKey |
GJSURZIOUXUGAL-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 4205-90-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 230.09 | Topological Polar Surface Area | 36.4 | ||
| Heavy Atom Count | 14 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 1 | |||
| XLogP |
1.6
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10522369
, 10527768
, 11110984
, 11110985
, 11113648
, 11120350
, 11120838
, 11121326
, 11121653
, 11122133
, 11335949
, 11361188
, 11362722
, 11364235
, 11365284
, 11366797
, 11367846
, 11369359
, 11370715
, 11370716
, 11371375
, 11373447
, 11374710
, 11376008
, 11377521
, 11462160
, 11466276
, 11467396
, 11484969
, 11485991
, 11489003
, 11490174
, 11492771
, 11495155
, 14822899
, 15172366
, 26697416
, 26697467
, 26751841
, 26751842
, 29221958
, 46508119
, 47216577
, 4807400
, 5991864
, 7847347
, 7978974
, 8151812
, 840960
, 841959
|
|||||
| ChEBI ID |
ChEBI:46632
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | OCT-1 | Transporter Info | Organic cation transporter 1 | Substrate | [2] | |
| OCT-2 | Transporter Info | Organic cation transporter 2 | Substrate | [2] | ||
| OCT-3 | Transporter Info | Organic cation transporter 3 | Substrate | [2] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Clonidine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145. | |||||
| 3 | Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.